Breast　cancer　(BCa)　has　become　the　leading　cause　of　death　in　women　worldwide.　Irrespective　of　advancement　in　cancer　treatments,　e.g.,　surgery,　radiation,　chemotherapy,　hormonal　therapy,　immunotherapy,　and　targeted　therapy,　recurrence　leading　to　metastasis　poses　the　greatest　threat　in　BCa　management.　BCa　receptors　estrogen　(ER),　progesterone　(PR),　and　human　epidermal　growth　factor　receptor-2　(HER2)　hold　significant　reputations　as　prognostic　and　predictive　biomarkers　in　therapeutic　decision-making.　Under　normal　physiological　conditions,　these　receptors　modulate　critical　biological　functions,　e.g.,　cell　migration,　proliferation,　and　apoptosis　events,　etc.　However,　aberrant　expression　causes　deviations,　triggering　signaling　course　to　adapt　permanent　switching　＂ON＂　mode.　The　later　events　induce　rapid　and　unrestrained　proliferation　leading　to　cancer.　As　conventional　ways　of　cancer　management　ultimately　lead　to　resistance;　therefore,　recently　targeted　therapies　have　been　extensively　studied　to　conquer　resistance.　Targeting　various　small　molecules　in　downstream　signaling　has　become　an　area　of　interest　in　scientific　society.　The　severity　of　cancer　converts　many　folds　soon　after　it　takes　on　a　migratory　approach　that　eventually　commences　metastasis.　Cancer　migration　comprises　protrusion　of　cytoplasm　at　the　leading　edge　of　the　migration　forward-facing,　establishing　adhesions　with　the　basic　cell-matrix,　disassembly　of　the　adhesions　at　the　back　end　of　the　cell,　and　actin-myosin　fiber　contractions　to　pull　the　bulk　of　the　cytoplasm　forward.　On　the　other　hand,　metastatic　progression　comprises　a　cascade　of　events,　including　invasion,　migration,　and　establishment　of　tumor　microenvironment.　The　progression　of　BCa　from　early　stage　to　metastatic　development　causes　remarkable　heterogeneity.　Interference　at　any　explicit　level　could　hamper　the　process,　and　it　has　thus　become　an　area　of　interest　for　scientists.　Metastasis　is　the　ultimate　cause　of　spreading　tumor　cells　to　invade　distant　organs.　Recently　small　molecule　inhibitors　of　protein　tyrosine　kinases,　which　can　cross　the　blood-brain　barrier,　have　become　a　center　point　of　research　for　investigators　in　developing　novel　treatment　strategies　against　BCa　management.